Year: 2026

“Totality of evidence” approach to evaluate SCENESSE® EXECUTIVE SUMMARYfinal European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated disease assessment tools agreed CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy CUV107 study (n=300) to commence in 2H 2026MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) — CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s drug SCENESSE® (afamelanotide) as a systemic vitiligo treatment. EMA’s Scientific Advice¹ Following over 12 months of interaction, two formal submissions and...

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gapWHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemicBasel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines...

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gapWHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemicEast Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines...

The Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) approved unaudited Telia Lietuva, AB Interim Financial Statements, prepared according to International Financial Reporting Standards as adopted by the European Union, for 3 months’ period ended 31 March 2026. First quarter of 2026 (compared with the same period a year ago):Revenue grew by 7.6% and amounted to EUR 128.8 million (EUR 119.8 million) Adjusted EBITDA up by 8.2% to EUR 52.2 million (EUR 48.3 million EBITDA increased by 7.0% and amounted to EUR 51.2 million (EUR 47.8 million) Profit for the period went up by 9.0% to EUR 24.6 million (EUR 22.6 million) Capital investments increased by 19.2% and amounted to EUR 11.3 million (EUR 9.5 million) Free cash flow went up by 28.6% and amounted to EUR 40.2 million (EUR 31.3 million)Comment by Giedrė Kaminskaitė-Salters,...

  Press Release April 24, 2026 Signify reports first quarter 2026 results with resilient margins and cash flow amid continued market softness Highlights 1Signify’s installed base of connected light points increased to 171 million in Q1 26 Sales of EUR 1,274 million with a CSG of -5.1% (Q1 25: -2.8%) Adj. EBITA margin of 6.5% (Q1 25: 8.0%) Net income of EUR 8 million including restructuring costs of EUR 63 million mainly related to the recently announced cost reduction program (Q1 25: EUR 67 million) Free cash flow of EUR 47 million (Q1 25: EUR 40 million) Signify launched its new Brighter Lives, Better World 2030 program, designed to expand the reach of impactful, energy and resource-efficient lighting to improve lives, save energy, and preserve resourcesEindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader...

IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, starts today its Proteus User Meeting 2026 in Belgium. Oncologists, physicists, clinicians from the most prestigious worldwide cancer care institutions across the Americas, Europe and Asia-Pacific will gather this week for the largest meeting of proton therapy experts. These three days of scientific exchange focuses on improving outcomes for cancer patients worldwide. This 2026 edition also marks a symbolic milestone: 25 years since the very first patient was treated with a Proteus® system. That...

(2026-04-24) Kitron today reported record quarterly revenue, operating profit and order backlog, driven by accelerating demand in the Defence/Aerospace market sector. Kitron’s revenue for the first quarter was EUR 272.7 million, an increase of 66 per cent from 164.6 million in the same quarter last year. The Defence/Aerospace market sector continued to lead, but all market sectors grew compared to a year ago. First-quarter operating profit (EBIT) was EUR 25.6 million, compared with 12.5 million in the same quarter last year. Profitability expressed as EBIT margin was 9.4 per cent, compared with 7.6 per cent in the same quarter last year. This is in line with the strategic target of maintaining an EBIT margin above 9 per cent. The order backlog ended at an all-time high of EUR 805.9 million, an increase of 54 per cent compared with...